ABBV · AbbVie Inc.

Track ABBV — free Ask ALVIS about ABBV

$250.94 -6.47 (-2.51%) At close · Jul 31

Market Cap

$454.79B

1.77B

Up next

Next earnings call

Oct 2, 2026 Est · unconfirmed · in 9 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 8, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Research

our published analysis of this company

Research Thesis July 31, 2026

Novo Nordisk's 1.3 million Wegovy pill TRxs meet a 50% WAC cut — and the bear case still wins

Novo Nordisk is the only name in the GLP-1 bellwether set guiding negative adjusted-sales growth for 2026 (-4% to -12% at CER), even as Wegovy pill TRxs hit around 1.3 million in Q1 2026 and the 1 January 2027 WAC reset to USD 675 locks in further realised-price compression.

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Moderate

Market backdrop VIX 16 · calm Equity put/call 0.61

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +12%

above

Price vs 50-day avg +5%

above

RSI (14) 51

neutral

MACD trend Negative

52-week position 80%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −4%

trailing

6-month return +12%

trailing

YTD return +11%

this year

Relative strength +4%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $238 › 200d $225 — 50d above 200d

Institutional flow Accumulating

2,036 of 4,094 funds reported for Jun 30 · net +1.8M sh shares · +115 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

1.28% of float · ▲ +3.3% MoM · 3.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

4,094 holders — near 3-yr high, broad support

Squeeze score 59

elevated · 0–100

Fundamentals

Fair

Revenue growth +9%

Y/Y

EPS growth −1%

Y/Y

Free cash flow $17.8B

Valuation P/E 126.8

rich

Buyback $1.8B

remaining

Balance sheet $59.3B

net debt

Quant / Vol

risk profile

Moderate

Volatility 26%

annualized · 1-yr

Max drawdown −18%

past year

ATR 2.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Jul 31, 2026

Adjusted Diluted EPS · 2026 Non-GAAP Lowered $13.87 – $14.07

Guided vs delivered · last 1 settled

Full year revenue full year

guided $60.5B

guided $60.5B $61.16B Beat +1.1%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+12% Bullish

Price vs 50-day avg

+5% Bullish

RSI (14)

51 Neutral

MACD trend

Negative Bearish

52-week position

80% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $238 › 200d $225 — 50d above 200d

Institutional flow Accumulating

2,036 of 4,094 funds reported for Jun 30 · net +1.8M sh shares · +115 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

1.28% of float · ▲ +3.3% MoM · 3.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

4,094 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $185 Now $251 · 80% 52-wk high $267

vs 200-day avg +12% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Adjusted diluted EPS non-GAAP	$3.65	second quarter ended June 30, 2026	—

adjusted gross margin ratio non-GAAP	84.7%	second quarter ended June 30, 2026	—

adjusted operating margin ratio non-GAAP	48.3%	second quarter ended June 30, 2026	—

adjusted R&D expense as a percent of net revenues non-GAAP	13.6%	second quarter ended June 30, 2026	—

adjusted tax rate non-GAAP	14.7%	second quarter ended June 30, 2026	—

Global Botox Cosmetic net revenues	$728M	second quarter ended June 30, 2026	—
Global Botox Therapeutic net revenues	$1.04B	second quarter ended June 30, 2026	—
Global Elahere net revenues	$211M	second quarter ended June 30, 2026	—
Global Humira net revenues	$756M	second quarter ended June 30, 2026	—
Global Imbruvica net revenues	$532M	second quarter ended June 30, 2026	—
Global Juvederm net revenues	$245M	second quarter ended June 30, 2026	—
Global net revenues from the aesthetics portfolio	$1.28B	second quarter ended June 30, 2026	—
Global net revenues from the immunology portfolio	$8.79B	second quarter ended June 30, 2026	—
Global net revenues from the neuroscience portfolio	$3.23B	second quarter ended June 30, 2026	—
Global Qulipta net revenues	$350M	second quarter ended June 30, 2026	—
Global Rinvoq net revenues	$2.53B	second quarter ended June 30, 2026	—
Global Skyrizi net revenues	$5.51B	second quarter ended June 30, 2026	—
Global Ubrelvy net revenues	$392M	second quarter ended June 30, 2026	—
Global Venclexta net revenues	$771M	second quarter ended June 30, 2026	—
Global Vraylar net revenues	$1.07B	second quarter ended June 30, 2026	—
Global Vyalev net revenues	$256M	second quarter ended June 30, 2026	—
adjusted SG&A expense as a percent of net revenues non-GAAP	22.7%	first quarter	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Drug Manufacturers - General — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ABBV AbbVie Inc. this stock	$454.79B	+10.7%	+8.6%	126.8	1.3%
LLY ELI LILLY & Co	$1.08T	+7.1%	+44.7%	40.8	1.1%
JNJ Johnson & Johnson	$616.50B	+24.5%	+6.0%	29.7	1.1%
MRK Merck & Co., Inc.	$320.56B	+25.5%	+1.4%	36.6	1.2%
NVS Novartis AG	$296.80B	+16.7%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

4,160

% held: 71.8%
Reported: 2,036 of 4,094
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

1,435

View

Short & Settlement

Short Interest Rising

Shares short

22.6M

Days to cover: 3.5d
Change: +733.3K sh

View

Short Volume

Short vol %

50%

As of: Jul 31, 2026

Short Total

View

Fails to Deliver

FTD shares

2.3K

Value: $569.8K
As of: Jul 13, 2026

View

Off-Exchange

Off-exchange %

55.8%

Week of: Jul 6, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Josh Gottheimer

Amount: $1.0K–$15.0K
Traded: May 5, 2026

View

Financials

Revenue (FY)

$61.2B

Net income (FY): $4.2B
EPS diluted: $2.36

View

Buybacks

Authorized

$10.0B

Remaining: $1.8B

Spent Remaining

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 31, 2026
This year: 15

View

Proposed Sales

Value

$2.8M

Shares: 13.0K
Filed: May 26, 2026

View

Earnings & Events

Earnings Calls

Last call

Jul 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ABBV	-3.3%	-3.9%	+12.3%	-0.3%	+10.7%
SPY	+1.1%	+0.3%	+8.2%	+0.0%	+9.6%
vs SPY	-4.4%	-4.2%	+4.1%	-0.3%	+1.2%

Capital returns

Latest dividend

$1.73 / share · ex Jul 15, 2026

Raised 5.5%

Paid (TTM)

$6.83 / share · 4 payouts

Dividend yield (TTM, derived)

2.72%

Buyback program · as of Mar 31, 2026

Authorized

$10.00B

Spent (derived)

$8.20B

Remaining

$1.80B

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1551152 CUSIP 00287Y109 13F (30d) 2029 filings 1981 filers Visit website Investor relations

ABBV · AbbVie Inc.

Price & Indicators

Up next

AI Brief

Equibles Research

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns